BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.
Ramirez, Pablo; Rettig, Michael P; Uy, Geoffrey L; Deych, Elena; Holt, Matthew S; Ritchey, Julie K; DiPersio, John F.
; 114(7): 1340-3, 2009 Aug 13.
Artigo em Inglês | MEDLINE | ID: mdl-19571319
Lateral Mobility and Nanoscale Spatial Arrangement of Chemokine-activated α4ß1 Integrins on T Cells.
Modeling the molecular basis for α4ß1 integrin antagonism.
Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13.
Facile synthesis and <sup>18</sup>F-radiolabeling of α<sub>4</sub>ß<sub>1</sub>-specific LLP2A-aryltrifluoroborate peptidomimetic conjugates.
Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists.
A concise synthesis of a very late antigen-4 antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid via reductive etherification.
Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion.
Effect of acute lung injury on VLA-4 and CXCR4 expression in resident and circulating hematopoietic stem/progenitor cells.
Inhibition of α4ß1 integrin increases ovarian cancer response to carboplatin.
Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.